More than with 177Lu-labeled PSMA ligands, xerostomia was the most common adverse effect in the cohorts studied [75,76,77,78] and sometimes required activity adjustment to improve tolerance [79,80,81]. The gene discussed is FOLH1; the disease is xerostomia.